Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $73,865 | $1,316 | $60,711 | $53,424 |
| Dep. & Amort. | $80,414 | $84,859 | $85,543 | $32,595 |
| Deferred Tax | -$20,136 | -$25,714 | -$26,324 | -$4,994 |
| Stock-Based Comp. | $27,755 | $26,759 | $17,568 | $17,910 |
| Change in WC | -$2,052 | -$9,137 | -$24,243 | $3,570 |
| Other Non-Cash | $12,105 | $33,002 | $3,571 | $24,622 |
| Operating Cash Flow | $171,951 | $111,085 | $116,826 | $127,127 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$725 | -$551 | -$412 | -$2,045 |
| Net Acquisitions | $0 | $0 | -$14 | -$311,692 |
| Inv. Purchases | -$688,013 | -$101,621 | -$406,990 | -$311,573 |
| Inv. Sales/Matur. | $498,862 | $370,901 | $190,739 | $530,509 |
| Other Inv. Act. | $9 | $0 | $14 | $12,888 |
| Investing Cash Flow | -$189,867 | $268,729 | -$216,663 | -$81,913 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$402,500 | $0 | -$137,515 |
| Stock Issued | $14,908 | $6,610 | $12,423 | $7,095 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$2,715 | -$1,990 | -$22,900 | $0 |
| Financing Cash Flow | $12,193 | -$397,880 | -$10,477 | -$130,420 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$5,723 | -$18,066 | -$110,314 | -$85,206 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $75,054 | $93,120 | $203,434 | $288,640 |
| End Cash | $69,331 | $75,054 | $93,120 | $203,434 |
| Free Cash Flow | $171,226 | $110,534 | $116,414 | $125,082 |